Mom Survives Lymphoma, but Bills Linger

Her oncologist had never seen a patient with lymphoma that looked as hopeless as the case of Susan Rabinowitz. It was difficult to treat because of a five-pound tumor that had grown so unwieldy that “it looked like someone put an implant in my left breast and forgot the right one,” she said. The tumor originated in her chest muscle, and she was told that if she had not gone to a doctor when she did, it would have broken through her skin.

As for why she had not sought medical care sooner, Ms. Rabinowitz was trying alternative medicine, and did not have health insurance. Her husband had been laid off from work and she was too young for Medicare. Now in remission, she and her husband, who is now working, are struggling to pay over $20,000 in debt from her treatment.

I don’t know how we got through it,” she said. “I’m sure there are people way, way worse off than us, but it’s such a shock to go from high income to nothing. You check your pride.”
Her situation is being highlighted by The Neediest Cases Fund, administered by The New York Times Company Foundation, which raises millions of dollars to help thousands of individuals and families in distress. The assistance is rendered by seven New York City social service agencies. The Times pays the Fund's expenses, so all contributions go directly to provide services and cash assistance to the poor. If you’d like to help, contact:

The New York Times Neediest Cases Fund
4 Chase Metrotech Center
7th Floor East; Lockbox 5193
Brooklyn, NY 11245
http://www.nytimes.com/neediest
(800) 381-0075

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap